Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

/p>

2007 and Q4 2006 were $2.04:GBP1.00 and $1.92:GBP1.00 respectively.

(1) Non GAAP operating income, Non GAAP net income, Non GAAP diluted earnings per ordinary share and Non GAAP diluted earnings per ADS exclude intangible asset amortization charges, the accounting impact of share-based compensation and other items as described on page 8. For an explanation of why Shire's management believes that these non GAAP financial measures are useful to investors, see page 8. For a reconciliation of these non GAAP financial measures to the most directly comparable financial measures prepared in accordance with US GAAP, see pages 29-32.

2008 Outlook

R&D pipeline and new product launches in the next two years

Subject to obtaining relevant regulatory/governmental approvals, the following product launches are planned over the next two years:

- MEZAVANT in the EU and Canada during 2008;

- VYVANSE for use in adult patients in the US in Q2 2008 (PDUFA date April 28, 2008);
- DAYTRANA in the EU during H1 2009;

- INTUNIV in the US during H2 2009; and

- FOSRENOL in the CKD market in the US during 2009.

Financial Outlook Shire's business continues to perform strongly. We expect 2008 total revenue growth to be in the mid to high teens range with VYVANSE sales between $350 to $400 million, assuming that the adult indication is launched by mid year 2008.

Costs are estimated as follows:

- Phase 3(b) and Phase 4 studies to support existing launches in the Specialty Pharmaceuticals ("Specialty") business and new product development in both the Specialty and Human Genetic Therapies ("HGT") businesses will result in Research and Development ("R&D") spend for 2008 in the range of $450 to $475 million (or $465 to $490 million including FAS123R charge);

- Existing and planned launches will require additional advertising and promotional spend resulting in SG&A costs for 2008 in the range of $1,080 to
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report ... the current state of the global Propanol market with a focus on the Chinese ... Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and ...
(Date:7/30/2015)... Senomyx , Inc. (NASDAQ: SNMX ), a leading ... and commercialize novel flavor ingredients for the food, beverage, ... the second quarter 2015. "Moving into ... to achieve our commercial and financial goals," stated John ... "Since our last quarterly earnings report, our two partners ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... publie ses résultats pour le premier semestre 2015. ... les résultats. Visionner l,interview vidéo et ... Au sommaire de l,interview :  ... Moteurs de croissance - Diabète ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... of the Israeli,scientists, in a recent survey on creativity, ... them into a creative state and keep,them in this ... Project Mind Foundation and conducted by TNS Teleseker, the,survey ... was raised,one fifth of the total sample expressed a ...
... AMDL, Inc.,(Amex: ADL ), headquartered in ... Jilin, China, is a vertically integrated specialty,pharmaceutical ... Inc. ("JPI"), AMDL engages in the research, ... AMDL announced,that it has entered into an ...
... 2008 BioSpace, the world,s,leading online bioscience job board ... NC(TM) Career Fair on Thursday, May 1, 2008. The ... 11 am to 4 pm., (Logo: http://www.newscom.com/cgi-bin/prnh/20080222/CLF013LOGO ... Carolina will attend the,biotech job fair to meet in ...
Cached Biology Technology:Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science 2Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science 3AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries 2AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries 3Bioscience Career Fair in North Carolina Expected to Attract Well Qualified Job Seekers 2
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... be having a negative effect on pinyon pine reproduction, ... same woodland ecosystems, says a University of Colorado Boulder-led ... seed cone production declined by an average of about ... and northwestern Oklahoma over the past four decades, said ...
... in the Journal of Applied Physiology, Nutrition, and ... high fructose corn syrup (HFCS) and sucrose (table sugar) at ... fat in humans, a leading cause of non-alcoholic fatty liver ... body of science that high fructose corn syrup and table ...
... techniques may be increasing the severity of an outbreak ... in Central America and Mexico, according to a University ... current outbreak of coffee rust is the worst seen ... arrived in the region more than 40 years ago. ...
Cached Biology News:Southwest regional warming likely cause of pinyon pine cone decline, says CU study 2Southwest regional warming likely cause of pinyon pine cone decline, says CU study 3New study finds neither HFCS nor table sugar increases liver fat under 'real world' conditions 2Modern growing methods may be culprit of 'coffee rust' fungal outbreak 2Modern growing methods may be culprit of 'coffee rust' fungal outbreak 3
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Biology Products: